Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat breast cancer

NCT ID NCT04721977

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding the drug tucatinib to two standard breast cancer medications (trastuzumab and capecitabine) can help control advanced HER2-positive breast cancer that has worsened after previous treatments. It involves about 66 people with cancer that has spread and cannot be removed by surgery. The main goal is to see if this three-drug combination shrinks tumors effectively and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aichi Cancer Center Hospital ( Site 1013)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Fukushima Medical University Hospital ( Site 1012)

    Fukushima, 960-1295, Japan

  • Hiroshima City Hiroshima Citizens Hospital ( Site 1024)

    Hiroshima, 730-8518, Japan

  • Hokkaido University Hospital ( Site 1022)

    Sapporo, Hokkaido, 060-8648, Japan

  • Hyogo Cancer Center ( Site 1005)

    Akashi, Hyōgo, 673-8558, Japan

  • Hyogo College of Medicine Hospital ( Site 1019)

    Nishinomiya, Hyōgo, 663-8501, Japan

  • Juntendo University Hospital ( Site 1025)

    Tokyo, 113-0033, Japan

  • Kanagawa Cancer Center ( Site 1010)

    Yokohama, Kanagawa, 241-8515, Japan

  • Kumamoto Shinto General Hospital ( Site 1007)

    Kumamoto, 862-8655, Japan

  • Medical Corporation Nahanishikai Nahanishi Clinic ( Site 1016)

    Naha, Okinawa, 901-0154, Japan

  • Nagoya University Hospital ( Site 1021)

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital ( Site 1003)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 1002)

    Kashiwa, Chiba, 2778577, Japan

  • National Cheng Kung University Hospital ( Site 3000)

    Dawan, Tainan, 704, Taiwan

  • National Hospital Organization Hokkaido Cancer Center ( Site 1017)

    Sapporo, Hokkaido, 003-0804, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 1009)

    Fukuoka, 811-1395, Japan

  • National Hospital Organization Osaka National Hospital ( Site 1001)

    Osaka, 540-0006, Japan

  • National Hospital Organization Shikoku Cancer Center ( Site 1014)

    Matsuyama, Ehime, 791-0280, Japan

  • Osaka International Cancer Institute ( Site 1004)

    Osaka, 541-8567, Japan

  • Saitama Cancer Center ( Site 1018)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Samsung Medical Center ( Site 2002)

    Seoul, 06351, South Korea

  • Seoul National University Hospital ( Site 2003)

    Seoul, 03080, South Korea

  • Severance Hospital ( Site 2001)

    Seoul, 03722, South Korea

  • Showa University Hospital ( Site 1023)

    Tokyo, 142-8666, Japan

  • Social medical corporation Hakuaikai Sagara Hospital ( Site 1008)

    Kagoshima, 892-0833, Japan

  • The Cancer Institute Hospital of JFCR ( Site 1015)

    Tokyo, 135-8550, Japan

  • Tokyo Medical University Hospital ( Site 1006)

    Tokyo, 160-0023, Japan

  • University of Tsukuba Hospital ( Site 1020)

    Tsukuba, Ibaraki, 305-8576, Japan

Conditions

Explore the condition pages connected to this study.

BREAST CANCER